Vascular Biogenics Stock Working Capital
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics fundamentals help investors to digest information that contributes to Vascular Biogenics' financial success or failures. It also enables traders to predict the movement of Vascular Stock. The fundamental analysis module provides a way to measure Vascular Biogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vascular Biogenics stock.
Vascular |
Vascular Biogenics Company Working Capital Analysis
Vascular Biogenics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Vascular Biogenics Working Capital | 15.42 M |
Most of Vascular Biogenics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vascular Biogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAs per the company's disclosures, Vascular Biogenics has a Working Capital of 15.42 M. This is 96.38% lower than that of the Biotechnology sector and 97.14% lower than that of the Health Care industry. The working capital for all United States stocks is 98.96% higher than that of the company.
Vascular Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vascular Biogenics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vascular Biogenics could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics of similar companies.Vascular Biogenics is currently under evaluation in working capital category among its peers.
Vascular Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 9.63 X | |||
| Revenue | 658 K | |||
| Gross Profit | 554 K | |||
| EBITDA | (31.16 M) | |||
| Net Income | (32.3 M) | |||
| Cash And Equivalents | 34.15 M | |||
| Cash Per Share | 0.49 X | |||
| Total Debt | 564 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 4.05 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (31.59 M) | |||
| Short Ratio | 0.55 X | |||
| Earnings Per Share | (0.18) X | |||
| Target Price | 5.0 | |||
| Beta | 0.71 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 29.66 M | |||
| Retained Earnings | (294.38 M) | |||
| Working Capital | 15.42 M | |||
| Current Asset | 38.59 M | |||
| Current Liabilities | 4.16 M | |||
| Z Score | -2.01 | |||
| Net Asset | 29.66 M |
About Vascular Biogenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vascular Biogenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vascular Biogenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vascular Biogenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |